Results 21 to 30 of about 122,915 (346)

Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]

, 2010
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V., Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +2 more
core   +2 more sources

Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations

BMJ Open, 2020
Introduction Transparent collaborations between patient organisations (POs) and clinical research sponsors (CRS) can identify and address the unmet needs of patients and caregivers.
Ilaria Galetti, Maureen Sauve, Catarina Leite, Joep Welling, Martina Gahlemann, Annelise Roennow, Robert J Riggs, Ann Tyrrell Kennedy, Edith Brown, Alex Gonzalez, Alexandra Paula Portales Guiraud, François Houÿez, Rob Camp, Annie Gilbert, Lizette Moros, Jose Luis Luna Flores, Friedrich Schmidt, Wiebke Sauter, Henrik Finnern   +18 more
doaj   +1 more source

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. [PDF]

, 2012
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
Jimenez, Sergio A., Lee, MD, Jason B., Mendoza, MD, Fabian A., Nagle, Sarah J.   +3 more
core   +3 more sources

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis

Frontiers in Immunology, 2018
Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc ...
Swati Bhattacharyya, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, John Varga   +7 more
doaj   +1 more source

Advanced Autoantibody Testing in Systemic Sclerosis

Diagnostics, 2023
Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication.
Kholoud Almaabdi, Zareen Ahmad, Sindhu R. Johnson   +2 more
doaj   +1 more source

Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis

iScience, 2021
Summary: The processes underlying synchronous multiple organ fibrosis in systemic sclerosis (SSc) remain poorly understood. Age-related pathologies are associated with organismal decline in nicotinamide adenine dinucleotide (NAD+) that is due to ...
Bo Shi, Wenxia Wang, Benjamin Korman, Li Kai, Qianqian Wang, Jun Wei, Swarna Bale, Roberta Goncalves Marangoni, Swati Bhattacharyya, Stephen Miller, Dan Xu, Mahzad Akbarpour, Paul Cheresh, Daniele Proccissi, Demirkan Gursel, Jair Machado Espindola-Netto, Claudia C.S. Chini, Guilherme C. de Oliveira, Johann E. Gudjonsson, Eduardo N. Chini, John Varga   +20 more
doaj   +1 more source

Localized scleroderma: clinical spectrum and therapeutic update [PDF]

Anais Brasileiros de Dermatologia, 2015
Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis ...
Mariana Figueiroa Careta, Ricardo Romiti
doaj   +2 more sources

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources

Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics

Pharmaceuticals, 2023
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune diseases.
Michael Macklin, Sudeep Yadav, Reem Jan, Pankti Reid   +3 more
doaj   +1 more source

From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution

Dermatology Research and Practice, 2018
Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods.
Giuggioli Dilia, Colaci Michele, Cocchiara Emanuele, Spinella Amelia, Lumetti Federica, Ferri Clodoveo   +5 more
doaj   +1 more source